风181013
Lv2
160 积分
2022-02-11 加入
-
Antibody-drug conjugates in cancer therapy: innovations, challenges, and future directions
7天前
已完结
-
Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy
12天前
已完结
-
Peptide–Drug Conjugates: An Emerging Direction for the Next Generation of Peptide Therapeutics
12天前
已完结
-
Exploring the next generation of antibody–drug conjugates
12天前
已完结
-
A global phase 3 study of serplulimab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (ASTRUM-004)
27天前
已完结
-
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
27天前
已完结
-
Low-dose versus standard-dose olanzapine with triple antiemetic therapy for prevention of highly emetogenic chemotherapy-induced nausea and vomiting in patients with solid tumours: a single-centre, open-label, non-inferiority, randomised, controlled, phase 3 trial
1个月前
已完结
-
Efficacy of rechallenge immunotherapy after immune monotherapy resistance in patients with advanced non-small cell lung cancer
2个月前
已完结
-
What to do after immune-checkpoint inhibitors failure in advanced non-small cell lung cancer: an expert opinion and review
2个月前
已完结
-
32P Untargeted metabolomics and lipidomics identified four subtypes of small cell lung cancer
2个月前
已完结